Search Articles

View query in Help articles search

Search Results (1 to 10 of 2799 Results)

Download search results: CSV END BibTex RIS


Development of a Sham Smartphone App for Opioid Use Disorder: Acceptability and Suitability Study

Development of a Sham Smartphone App for Opioid Use Disorder: Acceptability and Suitability Study

In 2018, the FDA approved re SET-O, an 84-day prescription digital therapeutic, to improve retention in outpatient treatment for OUD [15]. re SET-O received FDA approval after the completion of a randomized trial that used treatment as usual for the control condition. In doing so, the efficacy demonstrated by re SET-O may be attributable to having access to an app rather than the intervention provided within re SET-O itself.

Kierstyn S Gallegos, Jennifer S Potter, Van L King, Gregg Siegel, Leslie H Siegel, Elise N Marino

JMIR Form Res 2025;9:e71105